AN2 Therapeutics, Inc. (ANTX): Submission of Matters to a Vote of Security Holders
AN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001880438 0001880438 2026-06-03 2026-06-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03,
How this was made
The 30-second read
Why it matters
This is a post-meeting disclosure of certified voting outcomes for two proposals: electing three Class I directors and ratifying the independent registered public accounting firm for FY ending Dec. 31, 2026.
Market read
Governance vote results are typically low-volatility, but they confirm board composition and auditor continuity for the coming fiscal year.
What to watch
Traders may still monitor whether any director changes or auditor issues foreshadow upcoming corporate actions, but this 8-K contains no such forward-looking disclosures.
Background
The company’s 8-K Item 5.07 summarizes matters submitted to a vote of security holders at its 2026 annual meeting.
Ticker impact
AN2 Therapeutics (ANTX) filed an 8-K reporting stockholder voting results for director elections and the auditor ratification at its June 3, 2026 annual meeting.
Low likelihood of a sustained price move; any reaction is likely muted unless tied to a broader contested governance narrative not present here.
The filing discloses vote tallies for director nominees and PricewaterhouseCoopers ratification, with no new strategy, financial guidance, or regulatory/clinical catalyst included.
Market effects
Minimal; governance/auditor ratification is broadly applicable and not a sector-level signal.
None indicated.
None indicated.
Counterpoint
If the vote margins were unusually close or contested, it could hint at governance friction; however, the article provides no context of opposition beyond vote counts.
Key entities
- issuerAN2 Therapeutics, Inc.
Nasdaq-listed company filing the 8-K with certified stockholder vote results.
- director_nomineeKabeer Aziz
Class I director nominee elected at the annual meeting.
- director_nomineeGilbert Lynn Marks, M.D.
Class I director nominee elected at the annual meeting.
- director_nomineeRob Readnour, Ph.D.
Class I director nominee elected at the annual meeting.
- auditorPricewaterhouseCoopers LLP
Ratified as independent registered public accounting firm for FY ending Dec. 31, 2026.
